CN108368101B - 选择性nr2b拮抗剂 - Google Patents

选择性nr2b拮抗剂 Download PDF

Info

Publication number
CN108368101B
CN108368101B CN201680073103.8A CN201680073103A CN108368101B CN 108368101 B CN108368101 B CN 108368101B CN 201680073103 A CN201680073103 A CN 201680073103A CN 108368101 B CN108368101 B CN 108368101B
Authority
CN
China
Prior art keywords
flow rate
column
compound
mobile phase
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680073103.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108368101A (zh
Inventor
I.伊斯拉姆
S.桑加蒂鲁帕蒂
J.S.瓦里尔
S.彻鲁库
P.舍蒂
J.E.马科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108368101A publication Critical patent/CN108368101A/zh
Application granted granted Critical
Publication of CN108368101B publication Critical patent/CN108368101B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680073103.8A 2015-10-14 2016-10-13 选择性nr2b拮抗剂 Active CN108368101B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3309DE2015 2015-10-14
IN3309/DEL/2015 2015-10-14
PCT/US2016/056716 WO2017066368A1 (en) 2015-10-14 2016-10-13 Selective nr2b antagonists

Publications (2)

Publication Number Publication Date
CN108368101A CN108368101A (zh) 2018-08-03
CN108368101B true CN108368101B (zh) 2022-03-15

Family

ID=57208377

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073103.8A Active CN108368101B (zh) 2015-10-14 2016-10-13 选择性nr2b拮抗剂

Country Status (13)

Country Link
US (2) US10501451B2 (cg-RX-API-DMAC10.html)
EP (1) EP3362447B1 (cg-RX-API-DMAC10.html)
JP (1) JP6843853B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180064507A (cg-RX-API-DMAC10.html)
CN (1) CN108368101B (cg-RX-API-DMAC10.html)
AU (1) AU2016340239A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018007181A2 (cg-RX-API-DMAC10.html)
CA (1) CA3001894A1 (cg-RX-API-DMAC10.html)
EA (1) EA201890764A1 (cg-RX-API-DMAC10.html)
ES (1) ES2822830T3 (cg-RX-API-DMAC10.html)
IL (1) IL258611A (cg-RX-API-DMAC10.html)
MX (1) MX2018004257A (cg-RX-API-DMAC10.html)
WO (1) WO2017066368A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018004256A (es) * 2015-10-14 2018-05-16 Squibb Bristol Myers Co Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
EA202191014A1 (ru) * 2018-10-17 2021-11-09 Бёрингер Ингельхайм Интернациональ Гмбх Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства
TW202035396A (zh) * 2018-10-17 2020-10-01 德商百靈佳殷格翰國際股份有限公司 4-吡啶基甲基-嗎啉衍生物及其作為藥物之用途
CN112888684B (zh) * 2018-10-17 2023-10-10 勃林格殷格翰国际有限公司 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
EP4255419A1 (en) * 2020-12-04 2023-10-11 Novartis AG Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression
CN113620896A (zh) * 2021-08-31 2021-11-09 青岛科技大学 2-(2-氯苯基)甲基-4,4-二甲基-3-异恶唑酮的制备方法
CN116063200A (zh) * 2022-12-12 2023-05-05 华南理工大学 一种异噁唑啉宠物用杀虫剂氟雷拉纳中间体及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
WO2011100585A1 (en) * 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
WO2015105929A1 (en) * 2014-01-09 2015-07-16 Bristol-Myers Squibb Company (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
WO2015105772A1 (en) * 2014-01-09 2015-07-16 Bristol-Myers Squibb Company Selective nr2b antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
KR20060017839A (ko) 2003-06-04 2006-02-27 머크 앤드 캄파니 인코포레이티드 Nmda/nr2b 길항제로서 3-플루오로-피페리딘
MXPA06003748A (es) 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 nmda 수용체 길항물질
JP2009067784A (ja) * 2007-08-21 2009-04-02 Shionogi & Co Ltd 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
WO2011100585A1 (en) * 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
WO2015105929A1 (en) * 2014-01-09 2015-07-16 Bristol-Myers Squibb Company (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
WO2015105772A1 (en) * 2014-01-09 2015-07-16 Bristol-Myers Squibb Company Selective nr2b antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists;Paola Zarantonello et al.,;《Bioorganic & Medicinal Chemistry Letters》;20110218;第21卷;第2059-2063页 *
芳甲酰烷基哌嗪类化合物的合成及抗脑缺氧缺血活性;李建其等;《中国药物化学杂志》;20060228;第16卷(第1期);第6-14页 *

Also Published As

Publication number Publication date
US10954225B2 (en) 2021-03-23
EP3362447A1 (en) 2018-08-22
MX2018004257A (es) 2018-05-16
CN108368101A (zh) 2018-08-03
BR112018007181A2 (pt) 2018-10-16
EA201890764A1 (ru) 2018-09-28
IL258611A (en) 2018-06-28
ES2822830T3 (es) 2021-05-05
EP3362447B1 (en) 2020-08-26
US20200115370A1 (en) 2020-04-16
US10501451B2 (en) 2019-12-10
JP6843853B2 (ja) 2021-03-17
AU2016340239A1 (en) 2018-05-31
KR20180064507A (ko) 2018-06-14
WO2017066368A1 (en) 2017-04-20
CA3001894A1 (en) 2017-04-20
JP2018530582A (ja) 2018-10-18
US20180312495A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
JP6843853B2 (ja) 選択的nr2bアンタゴニスト
TW202341983A (zh) 用於降解突變kras蛋白之化合物及其應用
AU2014212487B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
ES2672992T3 (es) Compuesto aromático
KR102311518B1 (ko) 선택적 nr2b 길항제
TWI851226B (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
CN112236423A (zh) 哌啶基-3-(芳氧基)丙酰胺和丙酸酯
EP3233077B1 (en) Dopamine d2 receptor ligands
KR20160101194A (ko) 정신 장애의 치료를 위한 (r)-3-((3s,4s)-3-플루오로-4-(4-히드록시페닐)피페리딘-1-일)-1-(4-메틸벤질)피롤리딘-2-온 및 그의 전구약물
TW202204342A (zh) N—(雜環基及雜環基烷基)—3—苯甲基吡啶—2—胺衍生物
JP2018536637A (ja) 選択的nr2bアンタゴニスト
AU2021291799A1 (en) Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro(3,4- b)pyridine-3-carboxylate compounds as Cav1.2 activators
CN112867508B (zh) 4-吡啶基甲基-吗啉衍生物及其作为药物的用途
WO1995025100A1 (fr) Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes
KR20260043134A (ko) Sstr4의 작용제로서 (2s,5r)-5-(하이드록시메틸)모르폴린-2-카복스아미드
WO2024233747A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
KR20250086775A (ko) 파타틴-유사 인산지질분해효소 도메인-함유 단백질 3(pnpla3) 개질제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant